NasdaqGS:PTCTBiotechs
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile
Biotech sentiment has improved following an FDA leadership change that investors view as easing regulatory hurdles for cell and gene therapies.
PTC Therapeutics, listed as NasdaqGS:PTCT, is among the companies seen as directly affected by this shift in perceived regulatory risk.
The change centers on the departure of an official viewed as cautious on accelerated approvals, which is drawing fresh attention to PTC's drug pipeline.
For PTC Therapeutics, trading at $65.67, this regulatory...